A PHASE IIA STUDY EVALUATING THE SAFETY AND TOLERABILITY OF UMBRALISIB AND IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) - Lunning, M.